Exelixis Inc (EXEL)

26.89
0.11 0.41
NASDAQ : Health Care
Prev Close 26.78
Open 26.71
Day Low/High 26.52 / 27.09
52 Wk Low/High 3.55 / 8.74
Volume 3.07M
Avg Volume 4.16M
Exchange NASDAQ
Shares Outstanding 293.90M
Market Cap 7.91B
EPS -0.30
P/E Ratio 112.12
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAV, ARCC, BID, CFG, ENSG, EXEL, GCAP, HAE, HMLP, LGND, MOMO, MTW, PBR, RYI Downgrades: AEUA, ATSG, ATW, LMNX, MOH, MSB, NBEV, PAGP, SAVE, TIS Initiations: MCRB, TWLO Read on to get TheStreet Quant Ratings' detailed report:

Exelixis Announces Second Quarter 2017 Financial Results And Provides Corporate Update

Exelixis Announces Second Quarter 2017 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development...

Exelixis-Discovered Compounds To Be Featured In 10 Presentations At ESMO 2017 Congress

Exelixis-Discovered Compounds To Be Featured In 10 Presentations At ESMO 2017 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 10 presentations at the European Society for Medical Oncology (ESMO) 2017 Congress in...

Exelixis Announces Settlement Of Dispute With Genentech Regarding Companies' Collaboration Agreement For Cobimetinib

Exelixis Announces Settlement Of Dispute With Genentech Regarding Companies' Collaboration Agreement For Cobimetinib

Exelixis, Inc. (NASDAQ:EXEL) announced today a settlement of the company's dispute with Genentech, a member of the Roche Group, concerning the parties' collaboration for the development and commercialization of cobimetinib,...

Carnival, Tableau Software, Groupon, Newell Brands: 'Mad Money' Lightning Round

Carnival, Tableau Software, Groupon, Newell Brands: 'Mad Money' Lightning Round

Jim Cramer is bullish on Carnival, Tableau Software, Groupon, Newell Brands and more.

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Jim Cramer says the earnings results we get this week will determine where stocks are headed for the rest of the quarter.

Exelixis To Release Second Quarter 2017 Financial Results On Wednesday, August 2, 2017

Exelixis To Release Second Quarter 2017 Financial Results On Wednesday, August 2, 2017

Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2017 financial results will be released on Wednesday, August 2, 2017 after the markets close.

Short Interest Decreases By 12.5% For EXEL

Short Interest Decreases By 12.5% For EXEL

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 2,216,627 share decrease in total short interest for Exelixis Inc , to 15,465,148, a decrease of 12.54% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Exelixis Has an Enviable Chart Pattern

Exelixis Has an Enviable Chart Pattern

The $30 area is probably up next.

Chart of the Day: Exelixis

The $30 area is probably up next.

Biotech Movers: Exelixis, Omeros, Inovio

Biotech Movers: Exelixis, Omeros, Inovio

Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10.

Exelixis And Bristol-Myers Squibb Initiate Phase 3 Trial Of Opdivo® In Combination With CABOMETYX™ Or Opdivo And Yervoy® In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Exelixis And Bristol-Myers Squibb Initiate Phase 3 Trial Of Opdivo® In Combination With CABOMETYX™ Or Opdivo And Yervoy® In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate Opdivo ® (nivolumab) in combination with CABOMETYX™...

The 10 Sectors Making Up for Retail and Autos: Cramer's 'Mad Money' Recap (Wednesday 7/5/17)

The 10 Sectors Making Up for Retail and Autos: Cramer's 'Mad Money' Recap (Wednesday 7/5/17)

Healthcare, defense and banking are among the sectors making up for the collapse in the retail and auto industries.

Exelixis, Lowe's, Synovus: 'Mad Money' Lightning Round (7/5/17)

Exelixis, Lowe's, Synovus: 'Mad Money' Lightning Round (7/5/17)

A look at stocks of interest to viewers that Jim Cramer commented on during Mad Money.

Exelixis Repays Deerfield Notes One Year Ahead Of Maturity Date, Addressing Last Major Source Of Indebtedness

Exelixis Repays Deerfield Notes One Year Ahead Of Maturity Date, Addressing Last Major Source Of Indebtedness

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has addressed its last major source of indebtedness by retiring the Deerfield Notes, a series of Secured Convertible Notes originally issued in July 2010 to entities...

Exelixis Announces Independent Radiology Committee Review Confirms Results From CABOSUN, The Phase 2 Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) announced today that the analysis of the review by a blinded independent radiology review committee (IRC) has confirmed the primary efficacy endpoint results of investigator-assessed...

Exelixis Announces Initiation Of Phase 1b Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of the dose-escalation stage of a phase 1b trial of cabozantinib in combination with atezolizumab (TECENTRIQ ®) in patients with locally advanced or...

Exelixis To Present At The William Blair & Co. 37th Annual Growth Stock Conference On June 13

Exelixis, Inc. (NASDAQ: EXEL) today announced that management will present a corporate overview at the William Blair Growth Stock Conference taking place June 13-14 in Chicago, IL.

Fewer Oars Make Market Tough Row to Hoe

Fewer Oars Make Market Tough Row to Hoe

Investors should be more cautious heading into the summer.

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday.

These Stocks Are Changing Direction

These Stocks Are Changing Direction

Finding bullish and bearish reversals in the market.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (NASDAQ: EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 19,000 shares of Exelixis common stock and stock options to purchase an aggregate of 38,000...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, DVN, EXEL, FMC, FSI, GLT, MEOH, MJCO, MOH, NVO, RPXC, TECH, WU, WWE Downgrades: CIGI, IPHI, QUOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Exelixis Announces First Quarter 2017 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the first quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development...

Exelixis To Present At The Deutsche Bank 42nd Annual Health Care Conference On May 3

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.

Exelixis To Release First Quarter 2017 Financial Results On Monday, May 1, 2017

Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2017 financial results will be released on Monday, May 1, 2017 after the markets close.